Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980557 | 0.93 | KDM4E (0.49) | ACHEKDM4EALDH1A1ORAI1POLB | |
| SCHEMBL4978018 | 0.91 | GAA (0.50) | ACHEKDM4EALDH1A1ORAI1POLB | |
| SCHEMBL4981561 | 0.91 | HSP90AB1 (0.47) | ACHEKDM4EALDH1A1POLBTDP1 | |
| SCHEMBL4980209 | 0.91 | POLB (0.52) | ACHEKDM4EALDH1A1POLBTDP1 | |
| SCHEMBL4973559 | 0.91 | KDM4E (0.59) | ACHEKDM4EALDH1A1ORAI1POLB | |
| SCHEMBL4978172 | 0.91 | KDM4E (0.45) | ACHEKDM4EALDH1A1ORAI1POLB | |
| SCHEMBL4979742 | 0.90 | ALDH1A1 (0.48) | KDM4EALDH1A1HSP90AB1TSHRKMT2A | |
| SCHEMBL4977142 | 0.89 | KDM4E (0.45) | ACHEKDM4EALDH1A1ORAI1POLB | |
| SCHEMBL4976502 | 0.88 | KDM4E (0.50) | KDM4EALDH1A1ORAI1POLBTDP1 | |
| SCHEMBL4979123 | 0.88 | SMN1; SMN2 (0.54) | ACHEKDM4EALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | ACHE 2948/4885KDM4E 1865/4885ALDH1A1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.